Page 85 - Haematologica Vol. 110 - January 2025

ARTICLE - HCT in elderly AML
and allogeneic hematopoietic cell transplantation for advanced
hematologic malignancies. JAMA. 2011;306(17):1874-1883.
19. Kröger N, Iacobelli S, Franke G-N, et al. Dose-reduced versus
standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a pro-spective randomized phase III study of the EBMT (RICMAC Trial). J Clin Oncol. 2017;35(19):2157-2164.
20. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92(7):2322-2333.
21. Andersen PK, Hansen MG, Klein JP. Regression analysis of restricted mean survival time based on pseudo-observations. Lifetime Data Anal. 2004;10(4):335-350.
22. Klein JP, Gerster M, Andersen PK, Tarima S, Perme MP. SAS and R functions to compute pseudo-values for censored data regression. Comput Methods Programs Biomed. 2008;89(3):289-300.
23. Andersen PK, Perme MP. Pseudo-observations in survival analysis. Stat Methods Med Res. 2010;(19):71-99.
24. Royston P, Parmar MKB. The use of restricted mean survival time to estimate the treat-ment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;30(19):2409-2421.
25. Royston P, Parmar MKB. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13:152.
26. A’Hern RP. Restricted mean survival time: an obligatory end point for time-to-event analysis in cancer trials? J Clin Oncol. 2016;34(28):3474-3476.
27. Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1):62-70.
28. Versluis J, Labopin M, Niederwieser D, et al. Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in
D. Niederwieser et al. first complete remission. Leukemia. 2015;29(1):51-57.
29. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579-590.
30. Hell S, Jentzsch M, Franke G-N, et al. Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning- Eudract #: 2007-002420-15. Bone Marrow Transplant. 2022;57(5):824-826.
31. Niederwieser D, Baldomero H, Bazuaye N, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022;107(5):1045-1053.
32. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89(8):3048-3054.
33. Bolaños-Meade J, Hamadani M, Wu J, et al. Post- transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388(25):2338-2348.
34. Wei AH, Döhner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383(26):2526-2537.
35. Saxena K, DiNardo C, Daver N, Konopleva M. SOHO tate of the art updates and next questions:harnessing apoptosis in AML. Clin Lymphoma Myeloma Leuk. 2022;22(3):133-139.
36. Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hemato-poietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35(11):1154-1161.
37. Sorror ML, Gooley TA, Storer BE, et al. An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML. Blood. 2023;141(3):295-308.
Haematologica | 110 January 2025
77